The Central Drugs Standard Control Organisation (CDSCO) has suspended the ethics committee of HCG Hospital, Bengaluru, for two years over alleged violations in the oversight of clinical trials.
The action follows an inspection that reportedly uncovered deficiencies in regulatory compliance and ethical review procedures. While the committee cannot approve new clinical studies during the suspension period, it has been instructed to continue monitoring ongoing trials and ensure participant safety.
The regulator’s move highlights growing scrutiny of clinical research practices in India and reinforces the need for strict adherence to ethical standards, transparency and patient protection in medical studies.